Arcutis Biotherapeutics reports third quarter 2026 financial results and incorporates prior 8-K disclosures regarding corporate governance. (Items: 5.02 of the Company's Current Report on Form 8-K filed with the SEC on August 5, 2026 (Prior Form 8-K), which information is incorporated herein b)